Pay in 4 interest-free payments of $43.75 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19
2(5):611-24
RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer
improvement of bone mineral density
KN-62 at a concentration of 3 µM has no effect on ATP-induced ethidium influx through the rat P2X7 receptor
TAK-875 (Fasiglifam) - GPR40 Agonist. CAS# 1374598-80-7 0083 8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19TAK 875 (Fasiglifam), CAS No. 1374598 80 7, is the potent, selective and orally bioavailable partial GPR40 agonist with an EC50 ~14 nM. It has binding affinity to the human GPR40 receptor with Ki of 38 nM and the rat GPR40 receptor with Ki of 140 nM. TAK 875 has no agonist potency to other members of the FFA receptor family with EC50 >10 M. The 2. 3 resolution co complex structure of hGPR40 TAK 875 reveals a unique binding mode of TAK 875 and suggests
US$ 68.00
US$ 65.00
US$ 85.00
US$ 38.00
US$ 125.00
US$ 36.00
US$ 85.00
US$ 48.00
US$ 38.00
US$ 100.00
US$ 68.00
US$ 38.00
US$ 118.00